Table Graph
      published meta-analysis   sensitivity analysis   studies

leflunomide in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsWang, 2020 1.00 [0.02; 52.54] 1.00[0.02; 52.54]Wang, 202010%48NAnot evaluable clinical deteriorationdetailed resultsWang, 2020 1.00 [0.02; 52.54] 1.00[0.02; 52.54]Wang, 202010%48NAnot evaluable related SAE (TRSAE)detailed resultsWang, 2020 2.04 [0.07; 63.93] 2.04[0.07; 63.93]Wang, 202010%48NAnot evaluable adverse eventsdetailed resultsWang, 2020 3.57 [0.93; 13.72] 3.57[0.93; 13.72]Wang, 202010%48NAnot evaluable0.55.01.0relative treatment effectwww.metaEvidence.org2024-05-02 01:05 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 568 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons